ATR 1072 in Participants With PRKAG2 Syndrome
← catalyst calendarNCT07738107 · readout ≤ 651 d
Sponsored by Atrium Therapeutics (industry) · RNA — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
37estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2026 | estimated | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cardiac Glycogenosis
- Cardiomyopathy
- Hypertrophic
- Wolff-Parkinson-White Syndrome
Intervention
- Drug: ATR 1072
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs)
measured From first dose through end of study (approximately 48 weeks per participant)
Permalink · RNA's whole pipeline · Catalyst calendar · Every registered study · What changed